Trial of Oxford’s promising COVID vaccine resumes after brief pause
London — Oxford University announced over the weekend that it was resuming a trial for avaccine it is developing with pharmaceutical company AstraZeneca. The move came less than a week after the in a U.K. patient.
In a statement, the university confirmed the restart across all of its U.K. clinical trial sites after regulators gave the go-ahead following the pause on Sunday.
“The independent review process has concluded and following the recommendations of both the independent safety review committee and the U.K. regulator, the MHRA, the trials will recommence in the U.K.,” it said.
The vaccine being developed by Oxford and AstraZeneca is widely perceived to be one of, if not the strongest contender among the dozens of coronavirus vaccines in various stages of testing around the world.
British Health Secretary Matt Hancock …continued .
[Source: CBS News]